Several medications were recently deemed the most effective for treating acute migraine, including triptans, dihydroergotamine (DHE), nonsteroidal anti-inflammatory drugs (NSAIDS), butorphanol nasal spray, and the combination medication of sumatriptan/naproxen and acetaminophen/aspirin/caffein). Several other migraine medications were considered “probably effective” or “possibly effective.” Continue Reading
Q. I had a migraine yesterday morning and took my medication to get rid of it. It got rid of my pounding pain, but about 2 hours later a portion of the right side of my face became numb. Within another 3 hours, the entire right side of my face was numb, my mouth was drooping, and my right arm and leg were heavy. As you can imagine, we thought I could be having a stroke. I am 43. We went to the emergency room, and by the time I arrived, even my speech was affected.
All CT scans came back clear. The doctors decided I was having a complex migraine and explained the headaches can present as though the patient is having a stroke. They gave me a migraine “cocktail” and massive steroids and within a half hour, my symptoms were much improved. I am still regaining more control even today.
What was so odd was that I had no pain. Have you heard of this kind of migraine before? Continue Reading
Last month the U.S. Food and Drug Administration (FDA) rejected Levadex ®, an inhaled form of the migraine medication, dihydroergotamine (DHE). This is the second time the agency has failed to approve the medication.
DHE has been used in migraine treatment for many years, but it is most effective when given intravenously or via intramuscular injection, requiring a hospital or clinic visit. A DHE nasal spray is also available but is slow to take effect. The inhaled form of the medication is meant to work quickly and can be used at home. Continue Reading
MAP Pharmaceuticals, Inc. recently announced that it had resubmitted its New Drug Application to the United States Food and Drug Administration (FDA) for Levadex®, an orally inhaled migraine drug for the potential acute treatment of migraine in adults. Continue Reading
MAP Pharmaceuticals recently announced plans to resubmit its new drug application to the United States Food and Drug Administration (FDA) for Levadex, an inhaled medication meant to treat acute migraine. Company officials recently met with representatives from the FDA and say they hope to resubmit the application in the third or fourth quarters of this year.
In March, the FDA sent a Complete Response Letter to the biopharmaceutical company, declining to approve the drug and citing concerns about the drug’s chemistry, manufacturing and controls. Now MAP Pharmaceuticals representatives say those issues have been resolved or will be dealt with as part of the resubmission of the application. Continue Reading